Serotonin in synucleinopathies

Behav Brain Res. 2023 May 8:445:114367. doi: 10.1016/j.bbr.2023.114367. Epub 2023 Feb 28.

Abstract

Dysfunction of the serotonergic system represents an important feature in synucleinopathies like Parkinson disease (PD), dementia with Lewy bodies (DLB) and Multiple system atrophy (MSA). Serotonergic fibers from the raphe nuclei (RN) extend broadly throughout the central nervous system, innervating several brain areas affected in synucleinopathies. Alterations of the serotonergic system are associated with non-motor symptoms or motor complications in PD as well as with autonomic features of MSA. Postmortem studies, data from transgenic animal models and imaging techniques greatly contributed to the understanding of this serotonergic pathophysiology in the past, even leading to preclinical and clinical candidate drug tests targeting different parts of the serotonergic system. In this article, we review most recent work extending the knowledge of the serotonergic system and highlighting its relevance for the pathophysiology of synucleinopathies.

Keywords: Dementia with Lewy bodies; Multiple system atrophy; Parkinson disease; Serotonin; Serotonin transporter.

Publication types

  • Review

MeSH terms

  • Humans
  • Lewy Body Disease* / complications
  • Lewy Body Disease* / diagnosis
  • Multiple System Atrophy* / complications
  • Multiple System Atrophy* / diagnosis
  • Parkinson Disease* / complications
  • Serotonin
  • Synucleinopathies* / complications
  • alpha-Synuclein / physiology

Substances

  • Serotonin
  • alpha-Synuclein